Celera Genomics
Article Abstract:
A comparative analysis of the company sales and financial details of Celera Genomics from 1998 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
Drugs, Celera Genomics Group, CRA
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Human Genome Sciences Inc
Article Abstract:
Human Genome Sciences Inc.'s products are being developed for commercialization and although the company will be unprofitable for the foreseeable future, shares are only for the most venturesome of investors.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Product information, Forecasts, trends, outlooks, Financial management, Facilities & equipment, Labor Distribution by Employer, Finance, Company investment, Investments, Statistics, Buildings and facilities, Human Genome Sciences Inc., HGSI, Company business forecast/projection, Company forecasts
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Biotechnology industry, Biotechnology industries, Securities, Company sales and earnings, Company earnings/profit, Company securities
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.